Hepatitis B Reactivation and Infection in People with HIV on Tenofovir-Sparing Antiretroviral Therapy
Open Forum Infectious Diseases · 07.11.2026
DOI: 10.1093/ofid/ofag731 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 07.11.2026. Verfasst von G C Haser und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
As more people with HIV (PWH) transition to tenofovir (TXF)-sparing antiretroviral therapy (ART), the risk of hepatitis B virus (HBV) reactivation (HBVr) and new infection (HBVi) is a concern.
Methods
We conducted a retrospective study of 5,776 PWH in the Centers for AIDS Research Network of Integrated Clinical Systems cohort without active HBV infection with ≥1 TXF-sparing ART regimen prescribed after 5/1/2014 and examined episodes of HBVi/r defined as new HBV surface antigen (HBsAg) positivity or HBV viremia. We calculated rate of HBVi/r over total time on TXF-sparing ART per 10,000 person-years.
Results
We identified 17 cases of HBVi/r over a median 5.3 years of follow up. The rate of HBVi was 3.9 per 10,000 person-years, and rate of HBVr was 6.0 per 10,000 person-years, with possible higher risk for those who were HBV surface antibody (HBsAb) negative at cohort entry and among those not on ART with no anti-HBV activity. Liver injury, defined as alanine aminotransferase lab value ≥ 100 U/L, occurred within 3 months in only one HBVi case.
Conclusions
HBVi/r on TXF-sparing ART was rare in this U.S. cohort. HBVi/r occurred in some with prior HBsAb positivity, but significant hepatic flares were not observed. When starting TXF-sparing ART, providers should check complete HBV serologies, offer initial or additional vaccination as needed, and monitor for potential HBVi/r.
Zitieren
APA
Haser, G. C., Lisha, N. E., Kim, H. N., Burkholder, G., Cachay, E. R., Crane, H. M., Delaney, J. A. C., Falade-Nwulia, O., Fleming, J., Kitahata, M. M., Pettit, A. C., Rutstein, S. E., Yendewa, G., Luetkemeyer, A. F., & Christopoulos, K. A. (2026). Hepatitis B Reactivation and Infection in People with HIV on Tenofovir-Sparing Antiretroviral Therapy. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofag731
Vancouver
Haser GC, Lisha NE, Kim HN, Burkholder G, Cachay ER, Crane HM, et al. Hepatitis B Reactivation and Infection in People with HIV on Tenofovir-Sparing Antiretroviral Therapy. Open Forum Infectious Diseases. 2026. doi:10.1093/ofid/ofag731
BibTeX
@article{Haser2026,
author = {Haser, G C and Lisha, N E and Kim, H N and Burkholder, G and Cachay, E R and Crane, H M and Delaney, J A C and Falade-Nwulia, O and Fleming, J and Kitahata, M M and Pettit, A C and Rutstein, S E and Yendewa, G and Luetkemeyer, A F and Christopoulos, K A},
title = {Hepatitis B Reactivation and Infection in People with HIV on Tenofovir-Sparing Antiretroviral Therapy},
journal = {Open Forum Infectious Diseases},
year = {2026},
doi = {10.1093/ofid/ofag731}
}
EUVIMED